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Abstract: New guidelines recommend the use of CT surveillance 
after a curative treatment for lung cancer as survivors have a 3–6% 
risk per person year of developing a second primary lung cancer. 
Our analysis of 107 patients with second primary lung cancer treated 
by stereotactic ablative radiotherapy showed a comparable 3 years 
overall survival (60%) and local control rate (89%) as for an initial 
lung cancer. Toxicity was uncommon, despite the fact that 73% of 
patients had undergone a prior (bi)lobectomy. Our findings indicate 
that CT surveillance is also appropriate in patients who may be unfit, 
or unwilling, to undergo surgery.
(J Thorac Oncol. 2014;9: 1222–1225)
After the curative treatment of a lung cancer, the risk of developing a second primary lung cancer (SPLC) ranges 
between 3% and 6% per person year.1 Recent guidelines rec-
ommend follow-up of such patients by CT-scans for the detec-
tion of a treatable relapse or new primary tumors.2,3 However, 
the role of routine CT surveillance in lung cancer survivors is 
controversial as no survival benefit has yet been demonstrated 
in patients with a recurrence and also because of concerns 
about the toxicity of curative therapies in this setting.4
Although many patients developing a SPLC may be 
candidates for a second resection,5 a substantial proportion 
may be ineligible because of comorbidities or impaired lung 
function. Less fit patients with early-stage non–small-cell lung 
cancer (NSCLC) are eminently suitable for stereotactic abla-
tive radiotherapy (SABR), a highly conformal hypofraction-
ated radiotherapy technique, with low toxicity and actuarial 
local control rates at 3 years of more than 90%.6 As there is 
limited literature on the outcomes of SABR for this indica-
tion,7,8 our goal was to evaluate local control and toxicity for a 
SPLC treated with SABR at a single institution and to deter-
mine whether there could be a benefit of CT surveillance in 
the less fit patients presenting with a SPLC.
MATERIALS AND METHODS
Patients undergoing SABR for early-stage NSCLC at 
the VU University Medical Center are registered in a prospec-
tive institutional database. Between April 2003 and January 
2013, 863 patients underwent SABR for stage I NSCLC. For 
this analysis, we identified patients with a prior history of lung 
cancer, in whom the minimum interval was 6 months between 
the diagnosis of the initial and second tumor, and the initial 
tumor was under control at time of diagnosis of the second 
tumor. A total of 107 patients with a metachronous SPLC 
were identified. Patients undergoing a pneumonectomy for the 
initial tumor followed by SABR for the SPLC have been the 
subject of an earlier publication,9 but were not excluded from 
this analysis. Baseline patient and tumor characteristics of the 
initial and second lung cancer were collected, including treat-
ment details. In accordance to the Medical Research Involving 
Human Subjects Act, The Netherlands, retrospective reviews 
are exempt from medical ethics review, and the informed con-
sent of patients was not sought.
Patient selection criteria, and our SABR treatment pro-
tocol, have been described previously.10,11 Briefly, staging was 
performed using FDG-PET-CT-scans, and all patients were 
discussed in a multidisciplinary tumor board. SABR was 
delivered to a biologically equivalent dose of ≥100 gray (Gy
10
), 
prescribed in 3, 5, or 8 fractions, depending on T-stage and the 
proximity to the mediastinum or chest wall. Standardized fol-
low-up took place at 3, 6, and 12 months and yearly thereafter.
Time to local, regional or distant failure was calculated 
from the start of SABR. Disease-free survival was defined as 
the time between the start of SABR and the occurrence of 
any failure. The treatment interval was defined as the time 
between the start of treatment for the initial tumor and that 
of SABR. Because of the limited data available on treating 
SPLC with SABR, we compared the outcomes of patients 
with SPLC with the outcomes of the 756 patients in our SABR 
database who were treated for a “first” primary lung cancer 
(FPLC; T1-2N0M0).
Copyright © 2014 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0908-1222
A Brief Report on Outcomes of Stereotactic Ablative 
Radiotherapy for a Second Primary Lung Cancer:  
Evidence in Support of Routine CT Surveillance
Gwendolyn H.M.J. Griffioen, MD, Frank J. Lagerwaard, MD, PhD, Cornelis J.A. Haasbeek, MD, PhD, 
Ben J. Slotman, MD, PhD, and Suresh Senan MRCP, FRCR, PhD
Department of Radiation Oncology, VU University Medical Center, 
Amsterdam, the Netherlands.
Disclosures: The Department of Radiation Oncology, VU University Medical 
Center has research agreements with Varian Medical Systems Inc., and 
BrainLab AG, Germany. F.L. has received travel support and honorarium 
from Varian Medical Systems and BrainLab. B.S. has received travel sup-
port and honorarium from Varian Medical Systems and BrainLab. S.S. 
has received speaker’s honoraria from Varian Medical Systems. All other 
authors declare no conflict of interest.
Address for correspondence: Gwendolyn Griffioen, Department of Radiation 
Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV 
Amsterdam, The Netherlands. E-mail: g.griffioen@vumc.nl
Brief Report
1223Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 Outcomes in Metachronous Second Primary Lung Cancer AQ2
Toxicity was scored using the Common Toxicity Criteria 
for Adverse Events version 4.0. Toxicity reported within 3 
months after SABR was labeled as “acute toxicity,” and all 
toxicity reported after 3 months of SABR was labeled as “late 
toxicity”. For all descriptive statistics and calculations, IBM 
SPSS version 20.0 was used. A p value less than 0.05 was 
considered statistically significant.
RESULTS
Baseline patient, tumor and treatment characteristics are 
summarized in Table 1. Patients treated for SPLC were pre-
dominately male (68%) with a median age of 72 years and a 
median Charlson comorbidity index of 3 (non-age-adjusted; 
range: 0–10). Nearly all (98%) of the second lesions showed 
FDG-PET uptake, and the two remaining lesions had shown 
growth on consecutive chest CT-scans.
Six patients were treated with SABR for a third primary 
lung tumor, a single patient for a fourth. The initial primary 
tumor was predominately stage I-II (79.4%) according to the 
7th tumor, nodes, metastasis (TNM) staging system, had squa-
mous cell carcinoma histology (46.7%), and most of these had 
been treated by (bi)lobectomy (72.9%). The median interval 
between the treatment of the initial and second tumor was 48 
months (range, 6–349). Histology of the SPLC was unknown 
in 76.6% and a multidisciplinary tumor board assessed the risk 
of malignancy to be high, in accordance with guidelines of the 
European Society for Medical Oncology.2 For 25 patients in 
whom pathology was available for both lesions, 64% had the 
same histology.
The median follow-up duration after treatment of 
SPLC was 46 months, calculated by the reversed Kaplan-
Meier method. The median overall survival (OS) was 39.9 
months, with a 1- and 3-year OS of 86% and 60%, respec-
tively (Fig. 1). The 3-year local, regional, and distant control 
rates were 89%, 91%, and 85%, respectively. The median dis-
ease-free survival was not reached and was 80% at 3 years. 
Twelve patients with a SPLC (11% of total) developed a third 
(or fourth) primary lung tumor at a median of 20 months after 
SABR (range, 7–36 months).
TABLE 1.  Patient, Tumor, and Treatment Characteristics 
(n = 107)
Characteristics n (%) or Median (Range)
Male gender 73 (68%)
Age at SPLC (years) 72 (50–90)
Treatment interval (months) 48 (6–349)
COPD 85 (79.4%)
Charlson Comorbidity Index 3 (0–10)
WHO Performance Score (PS) 1 (0–3)
Stage initial lung cancer (7th TNM) 
  Stage I 67 (62.6%)
  Stage II 18 (16.8%)
  Stage III 17 (15.9%)
  Stage IV 3 (2.8%)
  Unknown 2 (1.9%)
Treatment initial lung cancer 
  Lobectomy/bilobectomy/trimodality 78 (72.9%)
  Pneumonectomy 17 (15.9%)
  Wedge/segmentectomy 3 (2.8%)
  CRT 7 (6.5%)
  Palliative (chemo or RT) 2 (1.9%)
Histology initial lung cancer
  Squamous cell carcinoma 50 (46.7%)
  Adenocarcinoma 39 (36.4%)
  NSCLC 11 (10.3%)
  SCLC 1 (0.9%)
  Unknown 4 (3.7%)
  Double tumor—different histology 2 (1.9%)
Histology SPLC 11 (10.2%)
  Squamous cell carcinoma 10 (9.3%)
  Adenocarcinoma 4 (3.7%)
  NSCLC 82 (76.6%)
  Unknown
Histology initial lung cancer and SPLC 
  Same 16 (15.0%)
  Different 9 (8.4%)
  Unknown 82 (76.6%)
Stage SPLC (7th TNM) 
  T1aN0 41 (38.3%) 
  T1bN0 34 (31.8%)
  T2aN0 28 (26.2%)
  T2bN0 4 (3.7%)
Diameter SPLC (mm) 23 (9–69)
PTV SPLC (cc) 20.7 (4.4–135.5)
Fractionation scheme SPLC 5 (3–8)
Dose SPLC (Gy) 60 (54–60)
SPLC, second primary lung cancer; COPD, chronic Obstructive Pulmonary Disease; 
PTV, planning target volume; NSCLC, non–small-cell lung carcinoma; SCLC, small-cell 
lung carcinoma; CRT, chemo-radiation; chemo, chemotherapy; RT, radiotherapy; WHO, 
World Health Organization; TNM, tumor, node, metastasis.
FIGURE 1.  Kaplan-Meier curve for overall survival of patients 
treated with stereotactic ablative radiotherapy for metachro-
nous second primary lung cancer (SPLC; n = 107).
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Reported acute grade ≥3 toxicity included a single 
case of grade 3 brachial plexopathy at 2 months after SABR 
in a patient with a tumor located in the apex of the left lung. 
Acute radiation-induced pneumonitis necessitating steroids 
(grade 2) was observed in less than 1% of patients. Late radi-
ation-induced pneumonitis necessitating steroids was noted 
in 7% of patients. In addition, late grade ≥3 toxicity was 
reported in 3.7% of patients and included one case of grade 
3 hemoptysis, for which blood transfusion was required. A 
single patient experienced an embolism of the right pulmo-
nary artery (grade 4), in conjunction with a regional nodal 
failure. Two cases of grade 5 toxicity were observed; one 
patient experienced a bleeding in a post-SABR cavitation 
with secondary infection by aspergillus; another patient 
experienced hemoptysis and respiratory failure associated 
with a bronchial stricture.
A comparison with patients treated in the same period 
with SABR for a FPLC (n = 756) is illustrated in Figure 2 
and showed no significant differences with respect to OS 
(p = 0.73), local control (p = 0.24), regional control (p = 0.49) 
and distant control (p = 0.69).
DISCUSSION
Despite an estimated risk of 3–6% per person year of 
developing a SPLC, there is controversy regarding the use of 
routine CT scans after curative treatment of a primary lung 
cancer. There are concerns about the fitness of such patients 
to undergo a second curative therapy as decreases in quality 
of life after surgery are well recognized.12 We studied the out-
comes of a large cohort of patients with SPLC treated with 
SABR, an outpatient treatment involving up to eight high-
dose fractions delivered with extremely high precision.
FIGURE 2.  Kaplan-Meier curves comparing (A) overall survival and (B) local, (C) regional, and (D) distant control rates between 
patients treated with stereotactic ablative radiotherapy for a “first” primary lung cancer (FPLC; gray line, n = 756) and a meta-
chronous second primary lung cancer (SPLC; black line, n = 107)
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Our analysis revealed that the outcomes of SABR for 
SPLC are no different than for an initial presentation of an 
early-stage NSCLC, with a 3-year OS of 60% and local con-
trol rates of 89% at 3 years. Toxicity was uncommon despite a 
population with prior surgery.
Our findings support the current guidelines in North 
America and Europe recommending routine surveillance,2,3 
even in patients who may not be fit for further surgery. The 
observation that 11% of our patients developed a third (or 
fourth) primary lung cancer during follow-up after SABR 
emphasizes that lung cancer survivors remain at high risk for 
developing new primary lung tumors.
To the best of our knowledge, this is the largest series 
on SABR for SPLC. One publication on 62 SPLC patients 
reported a 4-year survival of 53%,7 and another on 48 pts 
reported a 2-year survival of 68 %.8 These data are broadly 
consistent with our findings.
A recent large surgical series of 161 cases of metachro-
nous SPLC, reported a 5-year survival of 60% compared with 
23% in our series.13 However, OS is generally superior in surgi-
cal cohorts as eligibility for surgery implies having fewer comor-
bidities and better lung function. This is also illustrated by the 
difference in the number of patients with prior pneumonectomy 
in the surgical series (4.3%) compared with our cohort (15.9%).
One limitation of our analysis is the fact that a patho-
logical diagnosis was not available in many cases of SPLC, 
which is in contrast to the situation before treatment of the 
initial lung cancer. However, previous work in the Dutch pop-
ulation has shown that the incidence of benign disease is low 
in surgical cases, after a multidisciplinary tumor board has 
made a clinical diagnosis of lung cancer.14,15 Another concern 
might be that the treated lesion represented a solitary metas-
tasis instead of SPLC. However, as the outcomes after SPLC 
are similar to outcomes after FPLC (Fig. 2), this is less likely. 
It could also have been argued that some of our patients were 
potentially operable, despite having undergone a previous ana-
tomical resection. However, a growing body of data on SABR 
from high-risk populations suggests that SABR achieves com-
parable local control and OS as with surgery.6 In conclusion, 
our findings indicate that CT surveillance is also appropriate 
in patients who may be unfit, or unwilling, to undergo surgery.
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